• Faecal Incontinence
    • Michael A Kamm
    • Michael A Kamm: Influence Statistics

      Michael A Kamm

      Michael A Kamm

      Show email address

      The Austin Hospital, Gastroenterology, Melbourne, Australia | University of Melbourne, Department of Medicine, Parkville, Australia | University of Melbourne, Medicine, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Michael A Kamm:Expert Impact

      Concepts for whichMichael A Kammhas direct influence:Faecal incontinence,Ulcerative colitis,Inflammatory bowel disease,Fecal incontinence,Sacral nerve stimulation,Crohns disease,Anal sphincter,Idiopathic megarectum.

      Michael A Kamm:KOL impact

      Concepts related to the work of other authors for whichfor which Michael A Kamm has influence:Inflammatory bowel disease,Ulcerative colitis,Fecal incontinence,Gut microbiota,Chronic constipation,Irritable bowel syndrome,Colorectal cancer.

      KOL Resume for Michael A Kamm


      The Austin Hospital, Gastroenterology, Melbourne, Australia


      Department of Medicine, The University of Melbourne, Melbourne, Australia.

      Melbourne, Vic., Australia


      Department of Gastroenterology, St Vincent's Hospital, Fitzroy, Victoria, Australia

      University of Melbourne

      St Vincent’s Hospital


      Department of Gastroenterology, St Vincent's Hospital, Melbourne, Australia


      Department of Gastroenterology, St Vincent’s Hospital and University of Melbourne, Melbourne, Australia

      University of Melbourne, Melbourne, VIC


      St Vincent's Hospital Melbourne and University of Melbourne, Melbourne, VIC 3065, Australia

      Imperial College, London, UK


      Imperial College London, London, United Kingdom;

      University of Melbourne Melbourne Victoria Australia


      Department of Pathology, University of Melbourne, Australia;

      Imperial College, London, United Kingdom; and


      St. Vincent's Hospital and University of Melbourne, Melbourne, Australia

      Department of Medicine, Imperial College London, London, UK


      St Vincent’s Hospital and University of Melbourne, Melbourne, Vic., Australia

      Imperial College London

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Michael A Kamm is among the top experts in the world.
      Concept World rank
      puborectalis pressure #1
      dcs intestinal dcs #1
      log eog patients #1
      ibd fam #1
      26 healthy volunteers #1
      rectocele biofeedback #1
      pocer study analysis #1
      role disease diagnosis #1
      9 months biofeedback #1
      function bowel actions #1
      length cent #1
      lachnospiraceae cluster #1
      neurogenic faecal incontinence #1
      methods 5asa release #1
      megacolon adult patients #1
      ptq long term #1
      clinical healing healing #1
      subjects r093877 #1
      28 standard treatment #1
      ibd dcs #1
      1 standard advice #1
      rectopexy lateral ligaments #1
      transsphincteric injection #1
      visceral autonomic #1
      thirteen consecutive patients #1
      caucasian 67 #1
      delivery late onset #1
      85540 #1
      luminal disease thalidomide #1
      prokinetic drug r093877 #1
      food exclusion remission #1
      laxatives 11 patients #1
      controlled trial strictures #1
      midwives perineal anatomy #1
      sns pound25 #1
      amplitude stimulation parameters #1
      ibs acute stress #1
      sns icer #1
      visceral sensitivity β #1
      treatment biofeedback #1
      cent anus #1
      vaginal delivery pntml #1
      incontinence internal #1
      diltiazem pretreatment mrp #1
      p004 slow transit #1
      physiological testing women #1
      fmt development evaluation #1
      day poor function #1
      mmx matrix #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Michael A Kamm

      KOL-Index: 17231

      BACKGROUND & AIMS: Crohn's disease (CD) usually recurs after intestinal resection; postoperative endoscopic monitoring and tailored treatment can reduce the chance of recurrence. We investigated whether monitoring levels of fecal calprotectin (FC) can substitute for endoscopic analysis of the mucosa.

      METHODS: We analyzed data collected from 135 participants in a prospective, randomized, controlled trial, performed at 17 hospitals in Australia and 1 hospital in New Zealand, that assessed ...

      Known for Surgery Patients | Fecal Calprotectin | 6 Months | Disease Recurrence | Intestinal Resection
      KOL-Index: 16351

      BACKGROUND & AIMS: SPD476 (MMX mesalamine), a novel, once-daily mesalamine formulation, uses MMX Multi Matrix System (MMX) technology to delay and extend delivery of active drug throughout the colon. We performed a randomized, double-blind, parallel-group, placebo-controlled, multicenter phase III study in patients with mild to moderately active ulcerative colitis.

      METHODS: Two hundred eighty patients with mild to moderately active ulcerative colitis received MMX mesalamine 2.4 g/day ...

      Known for Mmx Mesalamine | Active Ulcerative | Nonsteroidal Colitis | Week Patients | Sigmoidoscopy Score
      KOL-Index: 16098

      The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimbursement guidelines, and patient preferences guide the choice of first-line biological therapy for luminal Crohn's disease (CD). Infliximab (IFX) has the most extensive clinical trial data, but ...

      Known for Biological Therapy | London Position Statement | Monoclonal Antibodies | Ifx Patients | Loss Response
      KOL-Index: 16012

      BACKGROUND: Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximab is an effective maintenance therapy for patients with fistulas.

      METHODS: We performed a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of infliximab maintenance therapy in 306 adult patients with Crohn's disease and one or more draining abdominal or ...

      Known for Infliximab Maintenance Therapy | Patients Response | Crohns Disease Fistulas | Placebo Maintenance | Fistulizing Crohn
      KOL-Index: 15672

      BACKGROUND & AIMS: Inflammatory bowel diseases (IBD) are becoming more common in Asia, but epidemiologic data are lacking. The Asia-Pacific Crohn's and Colitis Epidemiology Study aimed to determine the incidence and phenotype of IBD in 8 countries across Asia and in Australia.

      METHODS: We performed a prospective, population-based study of IBD incidence in predefined catchment areas, collecting data for 1 year, starting on April 1, 2011. New cases were ascertained from multiple ...

      Known for Ibd Asia | Inflammatory Bowel | 100000 Individuals | Epidemiology Study | 95 Confidence Interval
      KOL-Index: 14549

      BACKGROUND: Most patients with Crohn's disease need an intestinal resection, but a majority will subsequently experience disease recurrence and require further surgery. This study aimed to identify the optimal strategy to prevent postoperative disease recurrence.

      METHODS: In this randomised trial, consecutive patients from 17 centres in Australia and New Zealand undergoing intestinal resection of all macroscopic Crohn's disease, with an endoscopically accessible anastomosis, received 3 ...

      Known for Intestinal Resection | Recurrence Patients | 6 Months | Randomised Trial | Colonoscopy Crohn
      KOL-Index: 14387

      BACKGROUND: Preliminary data suggest that short-term antibiotic therapy with a single drug is effective for the treatment of patients with pouchitis. However, some patients are resistant to treatment.

      AIM: To evaluate the therapeutic efficacy of a prolonged course of a combination of two antibiotics in patients with refractory or recurrent pouchitis, as well as its impact on their quality of life.

      METHODS: Patients with active refractory or recurrent pouchitis were recruited. This was ...

      Known for Patients Pouchitis | Quality Life | Metronidazole Ciprofloxacin | Bowel Disease | Activity Score
      KOL-Index: 14361

      BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) can induce remission in patients with ulcerative colitis (UC). In a randomized controlled trial of FMT in patients with active UC, we aimed to identify bacterial taxonomic and functional factors associated with response to therapy.

      METHODS: We performed a double-blind trial of 81 patients with active UC randomly assigned to groups that received an initial colonoscopic infusion and then intensive multidonor FMT or placebo enemas, 5 ...

      Known for Patients Fmt | Ulcerative Colitis | Fecal Microbiota | Active Uc | Specific Bacteria
      KOL-Index: 14144

      BACKGROUND: The intestinal microbiota is implicated in the pathogenesis of ulcerative colitis. Faecal microbiota transplantation is a novel form of therapeutic microbial manipulation, but its efficacy in ulcerative colitis is uncertain. We aimed to establish the efficacy of intensive-dosing, multidonor, faecal microbiota transplantation in active ulcerative colitis.

      METHODS: We conducted a multicentre, double-blind, randomised, placebo-controlled trial at three hospitals in Australia. We ...

      Known for Faecal Microbiota | Active Ulcerative | Controlled Trial | Randomised Placebo | Endoscopic Remission
      KOL-Index: 13954

      BACKGROUND & AIMS: To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab' fragment of anti-tumor necrosis factor, CDP870) in Crohn's disease.

      METHODS: In a placebo-controlled, phase II study, 292 patients with moderate to severe Crohn's disease received subcutaneous certolizumab 100, 200, or 400 mg or placebo at weeks 0, 4, and 8. The primary end point was the percentage of patients with a clinical response at week 12 (a Crohn's Disease Activity ...

      Known for Certolizumab Pegol | Placebo Week | Patients Clinical Response | Polyethylene Glycols | Adult Antibodies
      KOL-Index: 13948

      Irritable Bowel Syndrome (IBS) is a common condition affecting around 10-20% of the population and associated with poorer psychological well-being and quality of life. The aim of the current study was to explore the efficacy of the Common Sense Model (CSM) using Structural Equation Modelling (SEM) in an IBS cohort. One hundred and thirty-one IBS patients (29 males, 102 females, mean age 38 years) participating in the IBSclinic.org.au pre-intervention assessment were included. Measures ...

      Known for Visceral Sensitivity | Illness Perceptions | Bowel Syndrome | Symptom Severity | Psychological Distress
      KOL-Index: 13598

      BACKGROUND & AIMS: SPD476 (LIALDA in the US; MEZAVANT in the EU; otherwise known as MMX mesalamine; Shire Pharmaceuticals Inc., Wayne, PA, under license from Giuliani SpA, Milan, Italy) is a novel, once-daily, high-strength (1.2 g/tablet) formulation of mesalamine, utilizing MMX Multi Matrix System (MMX) technology designed to deliver the active drug throughout the colon. We performed a double-blind, multicenter study, comparing MMX mesalamine vs placebo for the treatment of active ...

      Known for Mmx Mesalamine | Active Ulcerative Colitis | Day Daily | Endoscopic Remission | 8 Weeks
      KOL-Index: 13096

      OBJECTIVES: To determine (i) risk factors in the development of third degree obstetric tears and (ii) the success of primary sphincter repair.

      DESIGN: (i) Retrospective analysis of obstetric variables in 50 women who had sustained a third degree tear, compared with the remaining 8553 vaginal deliveries during the same period. (ii) Women who had sustained a third degree tear and had primary sphincter repair and control subjects were interviewed and investigated with anal endosonography, ...

      Known for Degree Tear | Primary Repair | Anal Sphincter | Obstetric Labor Complications | Pudendal Nerve Damage
      KOL-Index: 12991

      PURPOSE: The aim of lateral internal anal sphincterotomy when treating anal fissure is to divide the distal one-third to one-half of the internal anal sphincter. This study aimed to evaluate prospectively the extent of disruption to the internal anal sphincter following lateral anal internal sphincterotomy and also to establish the prevalence of symptoms of anal incontinence in these patients.

      METHODS: Fifteen patients with anal fissure (ten females and five males) had bowel symptoms ...

      Known for Internal Anal | Lateral Sphincterotomy | Sphincter Division | Fecal Incontinence | Surgical Procedures
      KOL-Index: 12952

      PURPOSE: We employed the Common Sense Model (CSM) of illness perceptions to examine the relative contribution of illness perceptions, stoma self-efficacy, and coping strategies in explaining anxiety and depression symptoms in patients with a fecal ostomy. The CSM suggests that the consequences of illness activity, such as psychological distress, are influenced by an individual's illness perceptions as well as what coping strategies they engage in.

      DESIGN: Descriptive, cross-sectional ...

      Known for Illness Perceptions | Coping Strategies | Psychological Morbidity | Anxiety Depression | Patients Stoma

      Key People For Faecal Incontinence

      Top KOLs in the world
      Michael A Kamm
      faecal incontinence ulcerative colitis inflammatory bowel disease
      Steven David Wexner
      rectal cancer fecal incontinence laparoscopic surgery
      Carolynne J Vaizey
      faecal incontinence sacral nerve stimulation tibial nerve
      Ralph John Nicholls
      restorative proctocolectomy faecal incontinence ulcerative colitis
      Ann C Lowry
      fecal incontinence subtotal colectomy stool consistency
      Robert D Madoff
      rectal cancer fecal incontinence prolonged thromboprophylaxis

      The Austin Hospital, Gastroenterology, Melbourne, Australia | University of Melbourne, Department of Medicine, Parkville, Australia | University of Melbourne, Medicine, Melbourne, Australia | St Vincent’s Hospital Melbourne, Department of Gastroenter

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.